Noxon

Drug Development for Fibrotic Lung Diseases

Startup

Noxon is a Nazareth-based startup in the Health Tech & Life Sciences sector, established in 2023. Drug Development for Fibrotic Lung Diseases. Key investors include NGT HealthCare II. The company has 1-10 employees. Core technologies: Biologicals.

The company follows a B2B2C business model. Product stage: R&D.

1
Rounds
1
Investors
1
Team
2023
Founded
Sector & Technology
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiologicals
At a Glance
Investors
Frequently Asked Questions
What does Noxon do?

Noxon develops a novel drug for oral treatment of fibrotic lung diseases. The developed drug, 3-cabamoyl-proxyl, is a stable organic radical belonging to the nitroxides group. Its product, 3-CP, which has a unique antioxidant property, has been shown to reduce airway inflammation, airway hyper-responsiveness, and other inflammatory mediators of the lung tissues, as seen in animal models of allergic asthma.

What sector is Noxon in?

Noxon operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Where is Noxon located?

Noxon is based in Wadi el-Haj St 13, Nazareth, Israel.

View Full Profile Classic View Website ↗